期刊文献+

伊立替康联合紫杉醇治疗复发上皮性卵巢癌的疗效观察 被引量:6

下载PDF
导出
摘要 目的观察伊立替康联合紫杉醇治疗复发上皮性卵巢癌的疗效。方法选择30例复发的耐铂上皮性卵巢癌,采用伊立替康联合紫杉醇治疗。伊立替康80mg/m2,静脉给药,第1、8、15天,28d为1周期;紫杉醇用药剂量和方法:每疗程紫杉醇总剂量为135mg/m2,溶于500ml 0.9%氯化钠溶液或5%葡萄糖液中进行静脉滴注,2~4个周期结束后评价疗效。结果 30例均可评价疗效,完全缓解率为6.67%,部分缓解率为23.33%,总缓解率43.33%,中位肿瘤进展时间为6.8个月。不良反应主要为骨髓抑制和迟发性腹泻,无化疗毒性相关死亡病例。结论伊立替康单药是治疗复发的耐铂上皮性卵巢癌安全有效的方案。
作者 于波
出处 《实用心脑肺血管病杂志》 2011年第6期943-944,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献7

  • 1刘芳,邹萍.血液病患者血清促红细胞生成素浓度检测的意义[J].临床医学,2003,23(5):23-24. 被引量:7
  • 2唐步坚,李力.复发上皮性卵巢癌的化学药物治疗[J].国际肿瘤学杂志,2005,32(1):68-71. 被引量:7
  • 3包乐纹,王国兴,张燮良.卵巢癌的二线化疗[J].中国肿瘤临床,2004,31(2):118-122. 被引量:10
  • 4Lauria R,Ferrari E,Tramontana S,et al.A phase I study of paclitaxel and epirubicin,without and with filgrastim,for the treatment of platinum-resistant advanced ovarian cancer[J].Oncology,1999,56:267-273. 被引量:1
  • 5Gershenson,Huinink W,Gore M,Carmichael J,et al.Topatecan versus paclitaxel for the treatment 0f recurrent epithelial ovarian cancer[J].J Clin Oncol,1997,15(6):2183-2193. 被引量:1
  • 6Piccart MJ,Gore M,Ten Bokkel Huinink W,et al.Docetaxel:an active new drug for treatment of advanced epithelial ovarian cancer[J].J Natl Cancer Inst,1995,87(9):676-681. 被引量:1
  • 7Markman M,Kennedy A,Webster K,et al.Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum[J].J Clin Oncol,2001,19(7):1901-1905. 被引量:1

二级参考文献68

  • 1李蓉生,张之南.基因重组人红细胞生成素治疗非肾性贫血[J].中华血液学杂志,1993,14(5):229-231. 被引量:9
  • 2[1]Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer[J]. J Repord Med, 2001, 46(7): 621~629 被引量:1
  • 3[2]Bodurka-Bevers D, Sun CC, Gershenson MD. Pharmacoeconomic considerations in treating ovarian cancer [J]. Pharmacoeconomics, 2000, 17(2): 133~150 被引量:1
  • 4[3]Landis SH, Murray T, Bolden S, et al. Cancer statistics1 1998[J]. CA Cancer J Clin, 1998, 48(6): 3~29 被引量:1
  • 5[4]Nahhas WA. Ovarian cancer. Current outlook on the deadly disease [J]. Postgrad Med, 1997, 102(3): 112~120 被引量:1
  • 6[5]Markman M, Hoskins W. Responses to "salvage" chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population[J]. J Clin Oncol, 1992,10(4):513~514 被引量:1
  • 7[6]Cremers GJ. Bolis G, Gone M, et al. Topetecan, an active drug in the second-line treatment of epithelial ovarian cancer,results of a large European phase 2 study [J]. J Clin Oncol,1996, 14(12): 3056~3061 被引量:1
  • 8[7]Thigpen JT, Blessing JA, Ball H, et al. Phase Ⅱ trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study[J]. J Clin Oncol, 1994, 12(9): 1748~1753 被引量:1
  • 9[8]Coeffic D. Paclitaxel, Topetecan and Cisplantin combination chemotherapy in advanced ovarian cancer [J]. Proc Annu Meeting Soc Gynecol Oncol, 2000, 19:1601 被引量:1
  • 10[9]Hall JB, Higgins RV, Naumaun RW. Phase 2 study of Topotecan and Cisplatin combination chemotherapy in stage 3/4 of recurrent endonetnial cancer[J]. Proc Annu Meeting Soc Gynecol Oncol, 2000, 19:1618 被引量:1

共引文献19

同被引文献65

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部